JP2004510816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004510816A5 JP2004510816A5 JP2002533856A JP2002533856A JP2004510816A5 JP 2004510816 A5 JP2004510816 A5 JP 2004510816A5 JP 2002533856 A JP2002533856 A JP 2002533856A JP 2002533856 A JP2002533856 A JP 2002533856A JP 2004510816 A5 JP2004510816 A5 JP 2004510816A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polyethylene glycol
- modafinil compound
- peg
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 45
- -1 modafinil compound Chemical class 0.000 description 17
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 15
- 229960001165 modafinil Drugs 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000019445 benzyl alcohol Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23948800P | 2000-10-11 | 2000-10-11 | |
| US09/974,473 US6489363B2 (en) | 2000-10-11 | 2001-10-10 | Pharmaceutical solutions of modafinil compounds |
| PCT/US2001/031685 WO2002030413A1 (en) | 2000-10-11 | 2001-10-11 | Pharmaceutical solutions of modafinil compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004510816A JP2004510816A (ja) | 2004-04-08 |
| JP2004510816A5 true JP2004510816A5 (enExample) | 2006-01-05 |
Family
ID=26932612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002533856A Pending JP2004510816A (ja) | 2000-10-11 | 2001-10-11 | モダフィニル化合物の製薬学的溶液 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6489363B2 (enExample) |
| EP (1) | EP1324755B1 (enExample) |
| JP (1) | JP2004510816A (enExample) |
| KR (1) | KR100846914B1 (enExample) |
| CN (1) | CN100518726C (enExample) |
| AT (1) | ATE478662T1 (enExample) |
| AU (2) | AU9678501A (enExample) |
| BG (1) | BG66221B1 (enExample) |
| BR (1) | BR0114813A (enExample) |
| CA (1) | CA2425218C (enExample) |
| CZ (1) | CZ2003966A3 (enExample) |
| DE (1) | DE60142913D1 (enExample) |
| EA (1) | EA005572B1 (enExample) |
| HU (1) | HU229424B1 (enExample) |
| IL (2) | IL155263A0 (enExample) |
| MX (1) | MXPA03003150A (enExample) |
| NO (1) | NO333096B1 (enExample) |
| NZ (1) | NZ525166A (enExample) |
| PL (1) | PL214879B1 (enExample) |
| SK (1) | SK287436B6 (enExample) |
| WO (1) | WO2002030413A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919378B2 (en) * | 2000-10-11 | 2005-07-19 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| KR100911952B1 (ko) * | 2000-10-11 | 2009-08-13 | 세파론, 인코포레이티드 | 모다피닐 화합물을 포함하는 조성물 |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| WO2004082624A2 (en) * | 2003-03-17 | 2004-09-30 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based neurorehabilitation of impaired neurological function associated with injury |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| US8153159B2 (en) * | 2003-09-18 | 2012-04-10 | Cephalon, Inc. | Modafinil modified release pharmaceutical compositions |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| BRPI0500520A (pt) * | 2005-02-16 | 2006-09-26 | Henry Jun Suzuki | uso de agentes flavorizantes aromáticos de alto ponto de fusão como agentes solubilizantes ou inibidores de cristalização em composições farmacêuticas |
| US20090123545A1 (en) * | 2005-07-21 | 2009-05-14 | Ron Eyal S | Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof |
| WO2008021341A2 (en) | 2006-08-14 | 2008-02-21 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
| CA2629979A1 (en) * | 2008-04-25 | 2009-10-25 | Pharmascience Inc. | Novel resveratrol compositions |
| FR2987266B1 (fr) | 2012-02-28 | 2014-12-19 | Debregeas Et Associes Pharma | Procede d'obtention d'une composition pharmaceutique a base de modafinil, composition pharmaceutique ainsi obtenue et son application |
| FR2987265B1 (fr) | 2012-02-28 | 2014-02-28 | Debregeas Et Associes Pharma | Composition pharmaceutique sous forme de sirop a base de modafinil, son procede de fabrication et son application |
| MX2015004973A (es) * | 2012-10-18 | 2015-07-17 | Abbvie Inc | Formulaciones de compuestos derivados de pirimidindiona. |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
-
2001
- 2001-10-10 US US09/974,473 patent/US6489363B2/en not_active Expired - Lifetime
- 2001-10-11 JP JP2002533856A patent/JP2004510816A/ja active Pending
- 2001-10-11 EA EA200300450A patent/EA005572B1/ru not_active IP Right Cessation
- 2001-10-11 BR BR0114813-3A patent/BR0114813A/pt active Search and Examination
- 2001-10-11 EP EP01977685A patent/EP1324755B1/en not_active Expired - Lifetime
- 2001-10-11 AT AT01977685T patent/ATE478662T1/de not_active IP Right Cessation
- 2001-10-11 CZ CZ2003966A patent/CZ2003966A3/cs unknown
- 2001-10-11 WO PCT/US2001/031685 patent/WO2002030413A1/en not_active Ceased
- 2001-10-11 IL IL15526301A patent/IL155263A0/xx active IP Right Review Request
- 2001-10-11 NZ NZ525166A patent/NZ525166A/en not_active IP Right Cessation
- 2001-10-11 AU AU9678501A patent/AU9678501A/xx active Pending
- 2001-10-11 PL PL361134A patent/PL214879B1/pl unknown
- 2001-10-11 MX MXPA03003150A patent/MXPA03003150A/es active IP Right Grant
- 2001-10-11 DE DE60142913T patent/DE60142913D1/de not_active Expired - Lifetime
- 2001-10-11 SK SK440-2003A patent/SK287436B6/sk not_active IP Right Cessation
- 2001-10-11 HU HU0302478A patent/HU229424B1/hu not_active IP Right Cessation
- 2001-10-11 CN CNB018171273A patent/CN100518726C/zh not_active Expired - Fee Related
- 2001-10-11 AU AU2001296785A patent/AU2001296785B2/en not_active Ceased
- 2001-10-11 KR KR1020037005057A patent/KR100846914B1/ko not_active Expired - Fee Related
- 2001-10-11 CA CA2425218A patent/CA2425218C/en not_active Expired - Fee Related
-
2003
- 2003-04-06 IL IL155263A patent/IL155263A/en not_active IP Right Cessation
- 2003-04-10 NO NO20031648A patent/NO333096B1/no not_active IP Right Cessation
- 2003-04-14 BG BG107720A patent/BG66221B1/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004510816A5 (enExample) | ||
| Laffleur et al. | Advances in drug delivery systems: Work in progress still needed? | |
| CA2425218A1 (en) | Pharmaceutical solutions of modafinil compounds | |
| JP4445590B2 (ja) | パロキセチン−レジン含有の経口液体組成物 | |
| JP2918691B2 (ja) | ラニチジン組成物 | |
| ES2705233T3 (es) | Conjugados de ácidos grasos de quetiapina, proceso para su fabricación y usos | |
| JP2005515966A5 (enExample) | ||
| KR20170012573A (ko) | 구강 삽입용 투여 제형 | |
| JP4669960B2 (ja) | 局所麻酔薬を含有する口中用または咽頭部用製剤 | |
| CA2432126A1 (en) | Complex of modafinil and cyclodextrin | |
| WO2004041245B1 (en) | Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases | |
| RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
| EP0315332B1 (en) | Antitussive liquid compositions containing phenol | |
| Datir | Recent advances in mucoadhesive buccal drug delivery system and its marketed scope and opportunities | |
| CA2425338A1 (en) | Compositions comprising modafinil compounds | |
| JP2003511396A5 (enExample) | ||
| JP2002528410A5 (enExample) | ||
| ES2942361T3 (es) | Métodos y composiciones para ésteres anticolinérgicos blandos | |
| JP2004514709A5 (enExample) | ||
| JP4746856B2 (ja) | ピラゾロン系製剤 | |
| ES2340164T3 (es) | Formulas orales de galantamina y sus aplicaciones. | |
| US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
| JP2003002827A5 (enExample) | ||
| JP3425949B2 (ja) | 医薬組成物 | |
| ES2241803T3 (es) | Forma galenica oral novedosa con liberacion prolongada de la molsidomina. |